Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDKeros Therapeutics Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 3 | -$1.20 | -$0.83 | -$1.02 |
| Q2 2026 | 5 | -$2.32 | -$0.60 | -$1.11 |
| Q3 2026 | 1 | -$0.80 | -$0.80 | -$0.80 |
| Q4 2026 | 1 | -$1.30 | -$1.30 | -$1.30 |
| Q1 2027 | 1 | -$1.05 | -$1.05 | -$1.05 |
| Q2 2027 | 1 | -$1.04 | -$1.04 | -$1.04 |
| Q3 2027 | 1 | -$0.77 | -$0.77 | -$0.77 |
| Q4 2027 | 1 | -$0.71 | -$0.71 | -$0.71 |
| Q1 2028 | 2 | -$1.01 | -$1.01 | -$1.01 |
| Q2 2028 | 2 | -$1.02 | -$1.02 | -$1.02 |
| Q3 2028 | 2 | -$1.02 | -$1.02 | -$1.02 |
| Q4 2028 | 2 | -$1.02 | -$1.02 | -$1.02 |
Keros Therapeutics Inc Earnings Date And Information
Keros Therapeutics Inc last posted its earnings results on Wednesday, March 4th, 2026. The company reported $-0.61969 earnings per share for the quarter, missing analysts' consensus estimates of $-0.49 by $0.12969. The company had revenue of 385.00 K for the quarter and had revenue of 244.06 M for the year. Keros Therapeutics Inc has generated $2 earnings per share over the last year ($2.3 diluted earnings per share) and currently has a price-to-earnings ratio of 5.89. Keros Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Keros Therapeutics Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/04/2026 | Q4 2025 | -$0.49 | -$0.38 | 0.11 | $3.67 M | $385.00 K |
| 11/05/2025 | Q3 2025 | -$1.11 | -$0.18 | 0.93 | $4.75 M | $14.26 M |
| 08/06/2025 | Q2 2025 | -$1.14 | -$0.76 | 0.38 | $4.02 M | $18.17 M |
| 05/06/2025 | Q1 2025 | -$0.01 | $3.66 | 3.67 | $1.87 M | $211.25 M |
| 02/26/2025 | Q4 2024 | -$1.36 | -$1.14 | 0.22 | $49.20 K | $3.04 M |
| 11/06/2024 | Q3 2024 | -$1.26 | -$1.47 | -0.21 | N/A | $388.00 K |
| 08/07/2024 | Q2 2024 | -$1.23 | -$1.25 | -0.02 | N/A | $37.00 K |
| 05/08/2024 | Q1 2024 | -$1.31 | -$1.46 | -0.15 | N/A | $83.00 K |
| 12/30/2023 | Q4 2023 | N/A | -$1.34 | N/A | N/A | $143.00 K |
| 11/06/2023 | Q3 2023 | -$1.34 | -$1.33 | 0.01 | N/A | $8.00 K |
| 08/07/2023 | Q2 2023 | -$1.34 | -$1.27 | 0.07 | N/A | $0 |
| 05/04/2023 | Q1 2023 | -$1.13 | -$1.15 | -0.02 | N/A | $0 |
| 03/03/2023 | Q4 2022 | -$1.12 | -$1.09 | 0.03 | N/A | $0 |
| 11/03/2022 | Q3 2022 | -$1.26 | -$0.75 | 0.51 | N/A | $0 |
| 08/04/2022 | Q2 2022 | -$1.07 | -$0.99 | 0.08 | N/A | $0 |
| 05/05/2022 | Q1 2022 | -$0.86 | -$1.01 | -0.15 | N/A | $0 |
| 03/09/2022 | Q4 2021 | -$0.94 | -$0.30 | 0.64 | N/A | $20.00 M |
| 11/04/2021 | Q3 2021 | -$0.72 | -$0.87 | -0.15 | N/A | $0 |
| 08/05/2021 | Q2 2021 | -$0.66 | -$0.67 | -0.01 | N/A | $100.00 K |
| 05/06/2021 | Q1 2021 | -$0.58 | -$0.68 | -0.1 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Keros Therapeutics Inc Earnings: FAQ's
The conference call for Keros Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Keros Therapeutics Inc's latest earnings report can be read online.
Keros Therapeutics Inc (:KROS) has a recorded annual revenue of $244.06 M.
Keros Therapeutics Inc (:KROS) has a recorded net income of $87.01 M.Keros Therapeutics Inc has generated $2.34 earnings per share over the last four quarters.
Keros Therapeutics Inc (:KROS) has a price-to-earnings ratio of 5.89 and price/earnings-to-growth ratio is 0.12.